Future prospects for Antimicrobial peptide development: peptidomimetics and antimicrobial combinations

Publication date

2026-02-17T08:36:49Z

2026-02-17T08:36:49Z

2021-02-24

2026-02-17T08:36:50Z



Abstract

Antimicrobial resistance is widely recognized as one of the major challenges of public health worldwide, as infections by multidrug-resistant (MDR) bacteria have reached worrisome levels. Three levels of antibiotic resistance have been described [Citation1]: i) multi-resistance (resistance to at least three different families of antimicrobials), ii) extreme resistance (resistance to all antimicrobials except colistin) and iii) pan-drug resistance (resistance to all available antimicrobials).

Document Type

Article


Accepted version

Language

English

Publisher

Informa Healthcare

Related items

Versió postprint del document publicat a: https://doi.org/10.1080/17460441.2021.1892072

Expert Opinion on Drug Discovery, 2021, vol. 16, num.6, p. 601-604

https://doi.org/10.1080/17460441.2021.1892072

Recommended citation

This citation was generated automatically.

Rights

(c) Informa Healthcare, 2021

This item appears in the following Collection(s)